ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $15,623,000 | +35.6% | 90,777 | -1.1% | 0.02% | +42.9% |
| Q2 2021 | $11,523,000 | -7.5% | 91,824 | -0.1% | 0.01% | -12.5% |
| Q1 2021 | $12,463,000 | +5.4% | 91,901 | -0.5% | 0.02% | -5.9% |
| Q4 2020 | $11,819,000 | +16.1% | 92,377 | +2.1% | 0.02% | +6.2% |
| Q3 2020 | $10,184,000 | +35.4% | 90,499 | +14.6% | 0.02% | +23.1% |
| Q2 2020 | $7,521,000 | +22.3% | 78,947 | +15.3% | 0.01% | 0.0% |
| Q1 2020 | $6,152,000 | +69.2% | 68,450 | -0.2% | 0.01% | +116.7% |
| Q4 2019 | $3,635,000 | +31.1% | 68,567 | -2.3% | 0.01% | +20.0% |
| Q3 2019 | $2,773,000 | -2.7% | 70,179 | +1.2% | 0.01% | -16.7% |
| Q2 2019 | $2,849,000 | -8.3% | 69,341 | +4.0% | 0.01% | 0.0% |
| Q1 2019 | $3,106,000 | +17.7% | 66,706 | +10.1% | 0.01% | 0.0% |
| Q4 2018 | $2,638,000 | -22.2% | 60,568 | +2.3% | 0.01% | -14.3% |
| Q3 2018 | $3,389,000 | +18.0% | 59,219 | -0.0% | 0.01% | +16.7% |
| Q2 2018 | $2,873,000 | +28.5% | 59,223 | +3.6% | 0.01% | +20.0% |
| Q1 2018 | $2,235,000 | -11.0% | 57,172 | -3.4% | 0.01% | 0.0% |
| Q4 2017 | $2,511,000 | +30.2% | 59,177 | +14.5% | 0.01% | +25.0% |
| Q3 2017 | $1,929,000 | +11.8% | 51,678 | -9.0% | 0.00% | 0.0% |
| Q2 2017 | $1,726,000 | +20.8% | 56,795 | +5.2% | 0.00% | +33.3% |
| Q1 2017 | $1,429,000 | -0.8% | 53,969 | -4.4% | 0.00% | 0.0% |
| Q4 2016 | $1,441,000 | -31.4% | 56,469 | -2.8% | 0.00% | -25.0% |
| Q3 2016 | $2,102,000 | +7.6% | 58,069 | +1.0% | 0.00% | 0.0% |
| Q2 2016 | $1,953,000 | +42.8% | 57,469 | +10.8% | 0.00% | +33.3% |
| Q1 2016 | $1,368,000 | -30.2% | 51,845 | +29.0% | 0.00% | -40.0% |
| Q4 2015 | $1,960,000 | +99.0% | 40,191 | +1.6% | 0.01% | +66.7% |
| Q3 2015 | $985,000 | -21.5% | 39,549 | -0.3% | 0.00% | 0.0% |
| Q2 2015 | $1,254,000 | +9.8% | 39,649 | +32.2% | 0.00% | 0.0% |
| Q1 2015 | $1,142,000 | -3.9% | 30,002 | -1.6% | 0.00% | 0.0% |
| Q4 2014 | $1,188,000 | +29.4% | 30,502 | +0.4% | 0.00% | +50.0% |
| Q3 2014 | $918,000 | -9.9% | 30,372 | +1.2% | 0.00% | -33.3% |
| Q2 2014 | $1,019,000 | +129.0% | 30,000 | +132.6% | 0.00% | +200.0% |
| Q1 2014 | $445,000 | -3.1% | 12,900 | +11.2% | 0.00% | 0.0% |
| Q4 2013 | $459,000 | – | 11,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |